Clinical trial
Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination
NCT03907423 is registered in ClinicalTrials.gov with Rehab Werida as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination
- Lead sponsor
- Rehab Werida
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- April 1, 2019
- Completion date
- January 31, 2021
- Enrollment
- 70 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.